Search results for " Glucose"

showing 10 items of 566 documents

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproteron…

2017

Abstract Background Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3 months to 1 year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. Materials and methods PubMed, Scopus, Google Scholar and ScienceDirect databases (2001–2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PC…

Blood Glucosemedicine.medical_specialtyTime Factorsmedicine.drug_classEndocrinology Diabetes and MetabolismBlood lipidsBlood Pressure030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDesogestrelInternal medicinemedicineHumansInsulinCyproterone AcetateClinical Trials as Topic030219 obstetrics & reproductive medicinebusiness.industryBody WeightCyproterone acetateDrospirenoneLipid Metabolismmedicine.diseasePolycystic ovaryEndocrinologychemistryMetabolomeFemaleProgestinsbusinessProgestinBody mass indexContraceptives OralPolycystic Ovary Syndromemedicine.drugMetabolism
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

Psychosocial Aspects of Continuous Glucose Monitoring

2016

Continuous glucose monitoring (CGM) systems provide people with diabetes with valuable real-time information on glucose trajectories and trends, thus offering opportunities for improving diabetes self-management. Ample evidence from clinical trials underscores CGM effectiveness for biomedical outcomes including HbA1C and hypoglycemia. However, interindividual variability in CGM uptake seems to be substantial: Neither do all individuals with diabetes adopt CGM readily in their diabetes self-management, nor do all of them benefit from CGM. In this article, we focus on CGM effects on quality of life and the potential role of psychosocial patient characteristics for determining the uptake and …

Blood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiomedical EngineeringPatient characteristics030209 endocrinology & metabolismBioengineeringHypoglycemia03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Diabetes mellitusDiabetes MellitusInternal MedicinemedicineHumans030212 general & internal medicineSpecial Section: Psychological Factors for Diabetes Technology Part IIIntensive care medicineContinuous glucose monitoringbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesmedicine.diseaseClinical diabetesClinical trialQuality of LifebusinessPsychosocialJournal of Diabetes Science and Technology
researchProduct

Irisinemia: A Novel Concept to Coin in Clinical Medicine?

2013

Skeletal muscle can express and release substances such as cytokines or other peptides capable of modulating metabolic processes. These cytokines, named ‘myokines', function as hormones either locally within the muscle or by targeting distant organs. A novel peptidic myokine named ‘irisin' has been recently identified. It has been noted that circulating irisin levels are lower in type 2 diabetes (T2D) compared with nondiabetic controls as well as in patients with chronic kidney disease. In addition, a negative correlation between the hemoglobin A1c (HbA1c) and circulating levels of irisin has been also observed. Thus, the blood concentration of irisin may reflect the metabolic status of pat…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesMedicine (miscellaneous)Type 2 diabetesMetabolic DiseasesDiabetes mellitusInternal medicineMyokineHumansMedicineObesityRenal Insufficiency ChronicMuscle SkeletalNutrition and Dieteticsbusiness.industrynutritional and metabolic diseasesSkeletal musclemedicine.diseaseObesityFibronectinsMetabolism disorderEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 2ImmunologyCytokinesbusinessHormoneKidney diseaseAnnals of Nutrition and Metabolism
researchProduct

Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model

2011

Anti-ischaemic drug mildronate suppresses fatty acid metabolism and increases glucose utilization in myocardium. It was proposed that it could produce a favourable effect on metabolic parameters and glucose transport in diabetic animals. Rats with streptozotocin diabetes mellitus were treated with mildronate (100 mg/kg daily, per os, 6 weeks). Therapeutic effect of mildronate was monitored by measuring animal weight, concentrations of blood glucose, insulin, blood triglycerides, free fatty acids, blood ketone bodies and cholesterol, glycated haemoglobin per cent (HbA1c%) and glucose tolerance. GLUT1 mRNA and protein expression in kidneys, heart, liver and muscles were studied by means of re…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentClinical BiochemistryBiochemistryStreptozocinDiabetes Mellitus Experimentalchemistry.chemical_compoundInternal medicineDiabetes mellitusDiabetes MellitusmedicineAnimalsBody SizeHypoglycemic AgentsInsulinRNA MessengerRats WistarTriglyceridesGlycated HemoglobinGlucose Transporter Type 1Glucose tolerance testmedicine.diagnostic_testFatty acid metabolismbiologyCholesterolbusiness.industryInsulinFatty AcidsGlucose transporternutritional and metabolic diseasesCell BiologyGeneral MedicineGlucose Tolerance Testmedicine.diseaseRatsEndocrinologychemistrybiology.proteinKetone bodiesGLUT1businessMethylhydrazinesCell Biochemistry and Function
researchProduct

Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome

2003

To determine the prevalence of insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) using baseline fasting blood measurements of glucose and insulin. Prospective clinical study. Academic endocrinology unit in Palermo, Italy. Two hundred and sixty-seven women with PCOS, consecutively evaluated, and 50 consecutively selected ovulating controls. Fasting blood was obtained for glucose and insulin measurements from all women. For 60 women with PCOS and 20 controls an insulin tolerance test (ITT) was also performed. Assessment of normal and abnormal values for fasting insulin, glucose/insulin ratio, and the calculated indices of the homeostasis model assessment (HOMA), quantitat…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentFasting insulinInsulin resistanceReference ValuesInternal medicinemedicineHomeostasisHumansInsulinPancreatic hormoneRetrospective Studiesbusiness.industryInsulinQuantitative insulin sensitivity check indexInsulin tolerance testInsulin Resistance Fasting physiology Insulin blood Polycystic Ovary SyndromeObstetrics and GynecologyFastingmedicine.diseasePolycystic ovaryEndocrinologyReproductive MedicineFemaleInsulin ResistancebusinessBody mass indexPolycystic Ovary Syndrome
researchProduct

Biosimilars and Novel Insulins.

2019

Background Insulin therapy is the mainstay of treatment for type 1 diabetes and may be necessary in type 2 diabetes. Current insulin analogues present a more physiological profile, are effective, and with less risk of hypoglycemia, but they are expensive. Biosimilar insulins should offer the advantages of insulin analogues at reduced costs. In addition, current rapid-acting insulin analogues are not fast enough to control excessive postprandial glucose excursions in many patients. Areas of uncertainty Biosimilar insulins demonstrated that are safe and effective, but interchangeability and automatic substitution remain an issue. Ultrafast-acting insulins should reduce postprandial hyperglyce…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInsulin GlargineType 2 diabetes030204 cardiovascular system & hematologyHypoglycemiaInsulin aspart03 medical and health sciences0302 clinical medicinemedicineInsulin lisproHumansHypoglycemic AgentsPharmacology (medical)030212 general & internal medicineIntensive care medicineBiosimilar PharmaceuticalsRandomized Controlled Trials as TopicPharmacologyGlycated HemoglobinType 1 diabetesInsulin Lisprobusiness.industryInsulin glargineInsulinnutritional and metabolic diseasesBiosimilarGeneral Medicinemedicine.diseaseDiabetes Mellitus Type 1Diabetes Mellitus Type 2Hyperglycemiabusinessmedicine.drugAmerican journal of therapeutics
researchProduct

Ambulatory Glucose Profile Applied to Flash Glucose Monitoring in Real Life: An Expert Opinion.

2016

The clinical benefits of real time continuous glucose monitoring (rtCGM) use have been well demonstrated in both CSII- and MDI-treated individuals in large clinical trials. However, recommendations for patient use of rtCGM in everyday life situations are lacking. This article provides guidance to clinicians and patients with type 1 diabetes (T1D) in effective use of rtCGM data, including glucose rate of change (ROC) arrows, for insulin dosing adjustments and other treatment decisions. The recommendations presented here are based on our own clinical experiences as endocrinologists, our personal experiences living with T1D using rtCGM, and findings from a recent survey of T1D patients who hav…

Blood Glucosemedicine.medical_specialtymultiple daily insulin injectionstype 1 diabetesEndocrinology Diabetes and MetabolismMonitoring ambulatoryBiomedical Engineeringflash glucose monitoringrate of changeMonitoring Ambulatory030209 endocrinology & metabolismBioengineeringglucose-monitoring systemMDI03 medical and health sciencesFlash (photography)0302 clinical medicineDiabetes mellitusBlood Glucose Self-MonitoringmedicineInternal MedicineIn real lifeambulatory glucose profile; diabetes; flash glucose monitoring; glucose-monitoring systems; glycemic control030212 general & internal medicineglucose-monitoring systemsIntensive care medicineambulatory glucose profileExpert TestimonyReview Articlesdiabetesbusiness.industryMedicine (all)Blood Glucose Self-MonitoringCSIImedicine.diseaseDiabetes Mellitus Type 1GlucosediabeteExpert opinioninsulin pumpAmbulatoryglucose profileglycemic controlcontinuous glucose monitoringMedical emergencybusinessJournal of diabetes science and technology
researchProduct

Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.

2019

The aim of this study is to assess the impact of a combination of berberine and silymarin on serum lipids and fasting plasma glucose (FPG) through a systematic review of literature and meta-analysis of the available randomized, double-blind, placebo-controlled clinical trials (RCTs). A systematic literature search in SCOPUS, PubMed-Medline, ISI Web of Science, and Google Scholar databases was conducted up to October 2, 2018, in order to identify RCTs assessing changes in plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and FPG during treatment with berberine and silymarin in combina…

Blood Glucosemedicine.medical_specialtysilymarinReviewsBlood lipidsberberine; cholesterol; fasting plasma glucose; meta-analysis; nutraceutical; silymarin; Berberine; Blood Glucose; Double-Blind Method; Fasting; Humans; Lipids; Randomized Controlled Trials as Topic; SilymarinReviewPlaceboGastroenterologymeta-analysiDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDouble-Blind MethodInternal medicineberberineMedicineHumansfasting plasma glucoseRandomized Controlled Trials as TopicPharmacology0303 health sciencesbusiness.industryCholesterolData synthesis030302 biochemistry & molecular biologycholesterolFastingLipidsClinical trialmeta-analysischemistrymeta‐analysis030220 oncology & carcinogenesisMetabolic effectsMeta-analysisnutraceuticalCardiology and Cardiovascular Medicinebusiness
researchProduct

The Ketogenic Diet and Sport: A Possible Marriage?

2015

The ketogenic diet (KD) is used widely as a weight loss strategy and, more rarely, as therapy for some diseases. In many sports, weight control is often necessary (boxing, weightlifting, wrestling, etc.), but the KD usually is not considered. Our hypothesis is that KD might be used to achieve fat loss without affecting strength/power performance negatively.

Blood Glucosemedicine.medical_treatmentPhysiologyPhysical Therapy Sports Therapy and RehabilitationBody Mass Indexskeletal muscle hypertrophyDiet Carbohydrate-RestrictedWeight lossWeight LossmedicineHumansBody Fat DistributionOrthopedics and Sports MedicineMuscle StrengthMuscle SkeletalBody fat distributionSportendurancebusiness.industryMedicine (all)Power performanceWeight controlWeight Loendurance; ketogenic diet; skeletal muscle hypertrophy; strength; weight loss; Blood Glucose; Body Fat Distribution; Body Mass Index; Diet Carbohydrate-Restricted; Humans; Muscle Strength; Muscle Skeletal; Physical Endurance; Sports; Ketogenic Diet; Weight Loss; Orthopedics and Sports Medicine; Physical Therapy Sports Therapy and Rehabilitation; Medicine (all)ketogenic dietPhysical Endurancemedicine.symptombusinessDiet KetogenicstrengthBody mass indexFat lossKetogenic dietSportsHuman
researchProduct